5:00 AM
Dec 18, 2018
 |  BC Extra  |  Financial News

Entrada raises $59M series A to take intracellular biologic into clinic

Entrada Therapeutics Inc. (Boston, Mass.) emerged from stealth Tuesday after raising $59 million in a series A round intended to propel its first intracellular biologics program into clinic.

Intracellular targets have proven challenging for small molecules and antibodies alike; small molecules require a defined, hydrophobic binding pocket, and antibodies cannot cross the cell's...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >